XNASSPRO
Market cap56mUSD
Dec 27, Last price
1.03USD
1D
9.13%
1Q
-21.37%
IPO
-91.09%
Name
Spero Therapeutics Inc
Chart & Performance
P/E
2.46
P/S
0.58
EPS
0.42
Div Yield, %
0.00%
Shrs. gr., 5y
27.06%
Rev. gr., 5y
89.43%
Revenues
97m
+99.13%
Net income
23m
P
CFO
-33m
L+326.79%
Dividend
Sep 16, 20150.015 USD/sh
Earnings
Mar 11, 2025
Profile
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 96,735 99.13% | 48,579 166.10% | 18,256 95.67% | ||||||
Cost of revenue | 77,361 | 85,623 | 107,344 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 19,374 | (37,044) | (89,088) | ||||||
NOPBT Margin | 20.03% | ||||||||
Operating Taxes | 2,598 | 1,613 | 1,545 | ||||||
Tax Rate | 13.41% | ||||||||
NOPAT | 16,776 | (38,657) | (90,633) | ||||||
Net income | 22,806 -147.48% | (48,028) -47.40% | (91,301) 17.78% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 221 | 35,210 | 64,107 | ||||||
BB yield | -0.28% | -54.15% | -12.96% | ||||||
| Debt | |||||||||
Debt current | 3,436 | 1,690 | 1,362 | ||||||
Long-term debt | 9,368 | 11,604 | 13,308 | ||||||
Deferred revenue | 10,825 | 22,166 | 8,786 | ||||||
Other long-term liabilities | 23,693 | 96 | 48,552 | ||||||
Net debt | (63,529) | (95,813) | (131,732) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (32,995) | (7,731) | (64,347) | ||||||
CAPEX | 39 | ||||||||
Cash from investing activities | 33,807 | 7,672 | |||||||
Cash from financing activities | 221 | (29,553) | 84,050 | ||||||
FCF | (1,934) | (36,593) | (89,406) | ||||||
| Balance | |||||||||
Cash | 76,333 | 109,107 | 146,402 | ||||||
Long term investments | |||||||||
Excess cash | 71,496 | 106,678 | 145,489 | ||||||
Stockholders' equity | (391,019) | (413,826) | (367,430) | ||||||
Invested Capital | 538,192 | 518,669 | 520,392 | ||||||
ROIC | 3.17% | ||||||||
ROCE | 13.16% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 52,989 | 37,585 | 30,896 | ||||||
Price | 1.47 -15.03% | 1.73 -89.19% | 16.01 -17.43% | ||||||
Market cap | 77,894 19.80% | 65,022 -86.85% | 494,641 13.96% | ||||||
EV | 14,365 | (30,791) | 362,912 | ||||||
EBITDA | 19,741 | (36,175) | (88,442) | ||||||
EV/EBITDA | 0.73 | 0.85 | |||||||
Interest | 2,605 | 1,940 | |||||||
Interest/NOPBT | |||||||||